Literature DB >> 6148214

The metabolism of avermectin-H2B1a and -H2B1b by pig liver microsomes.

S H Chiu, E Sestokas, R Taub, J L Smith, B Arison, A Y Lu.   

Abstract

The avermectins are a new class of macrocyclic lactone disaccharide antiparasitic agents derived from Streptomyces avermitilis. On incubation of avermectin-H2B1a and avermectin-H2B1b with pig liver microsomes, a group of metabolites slightly more polar than the parent compounds were generated. Two major metabolites have been isolated and purified by repetitive reversed phase and normal phase HPLC. Their structures were established to be the O-demethylation products of the parent compounds, i.e. 3''-O-desmethyl-H2B1a and 3''-O-desmethyl-H2B1b. The structure assignments were based on spectral results of UV, NMR, fast atom bombardment-mass spectrometry, and chemical derivatization studies including acid hydrolysis as well as fluorogenic reaction. Among the in vitro metabolites, there was only a trace amount of the polar metabolites 24-hydroxymethyl-H2B1a and 24-hydroxymethyl-H2B1b which were the major in vitro metabolites of avermectin-H2B1a and -H2B1b by steer or rat liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6148214

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

Review 1.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

2.  In vitro metabolism of 14C-moxidectin by hepatic microsomes from various species.

Authors:  J Dupuy; E Escudero; C Eeckhoutte; J F Sutra; P Galtier; M Alvinerie
Journal:  Vet Res Commun       Date:  2001-07       Impact factor: 2.459

3.  Identification of the metabolites of ivermectin in humans.

Authors:  Phornpimon Tipthara; Kevin C Kobylinski; Markus Godejohann; Borimas Hanboonkunupakarn; Alison Roth; John H Adams; Nicholas J White; Podjanee Jittamala; Nicholas P J Day; Joel Tarning
Journal:  Pharmacol Res Perspect       Date:  2021-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.